Among 371 randomized patients, 64.7% of sparsentan-treated patients achieved partial proteinuria remission -- defined by a urine protein-to-creatinine ratio (UPCR) of ≤1.5 g/g and >40% reduction ...

The primary endpoint was the percent reduction in UPCR (sampled from a 24-hr urine collection) at week 36 compared with baseline. The efficacy analysis was based on the first 270 patients in the ...

Findings from the APPEAR-C3G trial showed a 35% reduction in 24-hour UPCR from baseline (primary endpoint) in the iptacopan group compared with the placebo group. The Food and Drug Administration ...

The tablets are indicated for patients at risk of rapid disease progression, defined by a urine protein-to-creatinine ratio (UPCR) of 1.5 g/g or higher. Up to half of patients with persistent ...